Adiponectin and lipoprotein metabolism

Obesity Reviews

Volumn 14, Issue 12, 2013, Pages 939-949

  Christou, G A ^a   Kiortsis, D N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adiponectin; HDL; Lipoproteins; Triglycerides

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; ADIPONECTIN RECEPTOR; APOLIPOPROTEIN B100; ATORVASTATIN; BEZAFIBRATE; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPOPROTEIN A; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PRAVASTATIN; RESIN; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

BODY MASS; CARDIOVASCULAR DISEASE; DIET; GENE OVEREXPRESSION; LIPID ANALYSIS; LIPOLYSIS; LIPOPROTEIN METABOLISM; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADIPONECTIN; HDL; LIPOPROTEINS; TRIGLYCERIDES;

ADIPONECTIN; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, HDL; OBESITY; TRIGLYCERIDES;

EID: 84887509334     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12064     Document Type: Review

References (101)

1. Arita Y, Kihara S, Ouchi N etal. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
2. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34: 12-18.
3. Yamamoto Y, Hirose H, Saito I etal. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103: 137-142.
4. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-2769.
5. Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones (Athens) 2012; 11: 178-188.
6. Ezenwaka CE, Kalloo R, Uhlig M, Eckel J. Relationship between adiponectin and metabolic variables in Caribbean offspring of patients with type 2 diabetes mellitus. Horm Metab Res 2004; 36: 238-242.
7. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004; 53: 589-593.
8. Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 2003; 5: 349-353.
9. Baratta R, Amato S, Degano C etal. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 2004; 89: 2665-2671.
10. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
11. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4542-4548.
12. Aso Y, Yamamoto R, Wakabayashi S etal. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006; 55: 1954-1960.
13. Riestra P, García-Anguita A, Lasunción MA, Cano B, de Oya M, Garcés C. Relationship of adiponectin with metabolic syndrome components in pubertal children. Atherosclerosis 2011; 216: 467-470.
14. Shin MJ, Kim OY. Plasma adiponectin is associated with less atherogenic lipoprotein phenotype. Nutr Metab Cardiovasc Dis 2011; 21: 770-775.
15. Tsubakio-Yamamoto K, Sugimoto T, Nishida M etal. Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. Metabolism 2012; 61: 1763-1770.
16. von Eynatten M, Schneider JG, Humpert PM etal. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004; 27: 2925-2929.
17. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54: 795-802.
18. Chan DC, Watts GF, Ng TW etal. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005; 51: 578-585.
19. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005; 28: 2181-2186.
20. Kangas-Kontio T, Huotari A, Ruotsalainen H etal. Genetic and environmental determinants of total and high-molecular weight adiponectin in families with low HDL-cholesterol and early onset coronary heart disease. Atherosclerosis 2010; 210: 479-485.
21. Maruyama C, Ishibashi R, Araki R, Koike S, Hirose H, Maruyama T. HMW-adiponectin associates with triglyceride concentrations in type 1 diabetic patients. J Atheroscler Thromb 2009; 16: 207-216.
22. Shim CY, Park S, Kim JS etal. Association of plasma retinol-binding protein 4, adiponectin, and high molecular weight adiponectin with insulin resistance in non-diabetic hypertensive patients. Yonsei Med J 2010; 51: 375-384.
23. Kwon K, Jung SH, Choi C, Park SH. Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol 2005; 101: 385-390.
24. Im JA, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. Metabolism 2006; 55: 1546-1550.
25. Bergen WG, Mersmann HJ. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr 2005; 135: 2499-2502.
26. Van Linthout S, Foryst-Ludwig A, Spillmann F etal. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 2010; 210: 438-444.
27. Oku H, Matsuura F, Koseki M etal. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007; 581: 5029-5033.
28. Matsuura F, Oku H, Koseki M etal. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007; 358: 1091-1095.
29. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 2008; 57: 1824-1833.
30. Tsubakio-Yamamoto K, Matsuura F, Koseki M etal. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008; 375: 390-394.
31. Kitajima K, Miura S, Yamauchi T etal. Possibility of increasing cholesterol efflux by adiponectin and its receptors through the ATP binding cassette transporter A1 in HEK293T cells. Biochem Biophys Res Commun 2011; 411: 305-311.
32. Luo N, Wang X, Chung BH etal. Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo. Am J Physiol Endocrinol Metab 2011; 301: E180-E186.
33. Posadas-Sánchez R, Posadas-Romero C, Mendoza-Pérez E etal. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70mg/dl. Am J Cardiol 2012; 109: 636-641.
34. Dullaart RP, Groen AK, Dallinga-Thie GM, de Vries R, Sluiter WJ, van Tol A. Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. Eur J Endocrinol 2008; 158: 53-60.
35. Clarenbach JJ, Vega GL, Adams-Huet B, Considine RV, Ricks M, Sumner AE. Variability in postheparin hepatic lipase activity is associated with plasma adiponectin levels in African Americans. J Investig Med 2007; 55: 187-194.
36. Pilz S, Horejsi R, Möller R etal. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 2005; 90: 4792-4796.
37. Weiss R, Otvos JD, Flyvbjerg A etal. Adiponectin and lipoprotein particle size. Diabetes Care 2009; 32: 1317-1319.
38. Magge SN, Stettler N, Koren D etal. Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. J Clin Endocrinol Metab 2011; 96: 1549-1554.
39. Dullaart RP, de Vries R, Dallinga-Thie GM, van Tol A, Sluiter WJ. Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 2007; 1771: 113-118.
40. Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab 2009; 94: 989-997.
41. Vergès B, Petit JM, Duvillard L etal. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006; 26: 1364-1369.
42. Chan DC, Watts GF, Ooi EM, Chan DT, Wong AT, Barrett PH. Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men. Metabolism 2011; 60: 1482-1487.
43. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539.
44. Drew BG, Duffy SJ, Formosa MF etal. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119: 2103-2111.
45. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56: 320-328.
46. Esposito K, Pontillo A, Di Palo C etal. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804.
47. Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602.
48. Lejeune MP, Hukshorn CJ, Saris WH, Westerterp-Plantenga MS. Effects of very low calorie diet induced body weight loss with or without human pegylated recombinant leptin treatment on changes in ghrelin and adiponectin concentrations. Physiol Behav 2007; 91: 274-280.
49. Xydakis AM, Case CC, Jones PH etal. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004; 89: 2697-2703.
50. Arvidsson E, Viguerie N, Andersson I, Verdich C, Langin D, Arner P. Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes 2004; 53: 1966-1971.
51. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell LV. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004; 27: 629-630.
52. Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM. The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab 2005; 90: 4255-4259.
53. Delporte ML, Brichard SM, Hermans MP, Beguin C, Lambert M. Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf) 2003; 58: 22-29.
54. Kantartzis K, Rittig K, Balletshofer B etal. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 2006; 52: 1934-1942.
55. Hallikainen M, Kolehmainen M, Schwab U etal. Serum adipokines are associated with cholesterol metabolism in the metabolic syndrome. Clin Chim Acta 2007; 383: 126-132.
56. Okada T, Saito E, Kuromori Y etal. Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children. Atherosclerosis 2006; 188: 179-183.
57. Lucero D, Zago V, López GI etal. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 2011; 412: 143-147.
58. Vanhala M, Kumpula LS, Soininen P etal. High serum adiponectin is associated with favorable lipoprotein subclass profile in 6.4-year follow-up. Eur J Endocrinol 2011; 164: 549-552.
59. Lucero D, Zago V, López GH etal. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin Biochem 2012; 45: 293-297.
60. Wanninger J, Liebisch G, Schmitz G etal. Lipidomic analysis of the liver identifies changes of major and minor lipid species in adiponectin deficient mice. Exp Mol Pathol 2012; 94: 412-417.
61. Adiels M, Taskinen MR, Packard C etal. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-765.
62. Lapointe A, Tchernof A, Lamarche B etal. Plasma adiponectin concentration is strongly associated with VLDL-TG catabolism in postmenopausal women. Nutr Metab Cardiovasc Dis 2011; 21: 254-260.
63. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl) 2002; 80: 753-769.
64. Kobayashi J, Kusunoki M, Murase Y etal. Relationship of lipoprotein lipase and hepatic triacylglycerol lipase activity to serum adiponectin levels in Japanese hyperlipidemic men. Horm Metab Res 2005; 37: 505-509.
65. Combs TP, Pajvani UB, Berg AH etal. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145: 367-383.
66. Loucif Y, Méthot J, Tremblay K, Brisson D, Gaudet D. Contribution of adiponectin to the cardiometabolic risk of postmenopausal women with loss-of-function lipoprotein lipase gene mutations. Menopause 2011; 18: 558-562.
67. Magkos F, Fabbrini E, Patterson BW, Eagon JC, Klein S. Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects. Metabolism 2011; 60: 1641-1648.
68. Rubin D, Helwig U, Nothnagel M etal. Postprandial plasma adiponectin decreases after glucose and high fat meal and is independently associated with postprandial triacylglycerols but not with - 11388 promoter polymorphism. Br J Nutr 2008; 99: 76-82.
69. Matikainen N, Mänttäri S, Westerbacka J etal. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007; 92: 3052-3059.
70. Annuzzi G, Bozzetto L, Patti L etal. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. Metabolism 2010; 59: 567-574.
71. Takahashi R, Imamura A, Yoshikane M etal. Circulating malondialdehyde-modified low-density lipoprotein is strongly associated with very small low-density lipoprotein cholesterol concentrations in healthy men. Clin Chim Acta 2009; 399: 74-78.
72. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-271.
73. Blüher M, Bullen JW Jr, Lee JH etal. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006; 91: 2310-2316.
74. Staiger H, Kaltenbach S, Staiger K etal. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 2004; 53: 2195-2201.
75. Sakamoto K, Sakamoto T, Ogawa H, Kumamoto Joint Research on Hypercholesterolemia Investigators. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006; 28: 1012-1021.
76. Koh KK, Quon MJ, Han SH etal. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776-782.
77. Koh KK, Quon MJ, Han SH etal. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692.
78. Thongtang N, Ai M, Otokozawa S etal. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 2011; 107: 387-392.
79. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958-964.
80. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE. Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 2009; 150: 5262-5272.
81. Takagi T, Matsuda M, Abe M etal. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008; 196: 114-121.
82. Björkhem-Bergman L, Lindh JD, Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol 2011; 72: 164-165.
83. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes (Lond) 2005; 29(Suppl. 1): S17-S23.
84. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83-92.
85. Hiuge A, Tenenbaum A, Maeda N etal. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007; 27: 635-641.
86. Nakano S, Inada Y, Masuzaki H etal. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2007; 292: E1213-E1222.
87. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005; 28: 1419-1424.
88. Sharma AK, Raikwar SK, Kurmi MK, Srinivasan BP. Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats. Inflammopharmacology 2012; 21: 137-145.
89. Westphal S, Luley C. Preferential increase in high-molecular weight adiponectin after niacin. Atherosclerosis 2008; 198: 179-183.
90. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 2009; 296: E549-E558.
91. Gammelmark A, Madsen T, Varming K, Lundbye-Christensen S, Schmidt EB. Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects. Nutr Res 2012; 32: 15-23.
92. Satoh-Asahara N, Shimatsu A, Sasaki Y etal. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012; 35: 2631-2639.
93. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes. Obesity (Silver Spring) 2011; 19: 262-268.
94. Furukawa S, Fujita T, Shimabukuro M etal. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
95. Soares AF, Guichardant M, Cozzone D etal. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005; 38: 882-889.
96. Vargas ML, Almario RU, Buchan W, Kim K, Karakas SE. Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome. Metabolism 2011; 60: 1711-1718.
97. Lihn AS, Jessen N, Pedersen SB, Lund S, Richelsen B. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 2004; 316: 853-858.
98. Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond) 2009; 116: 1-16.
99. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536-541.
100. Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 2010; 59: 921-926.
101. Takebayashi K, Suetsugu M, Matsumoto S, Aso Y, Inukai T. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 2009; 102: 361-368.